CMAJ 2020

Immune checkpoint inhibitors (ICI’s) are increasingly used in cancer immunotherapy, and have shown unprecedented survival benefit in a number of malignancies with historically poor prognoses and limited therapeutic options. However, enhancing the immune response can result in immune-related adverse events (irAEs) that can affect any organ system. Treatment of these events typically requires delayed administration of the ICI and immunosuppressive therapy. Early recognition along with timely and appropriate specialist consultation is key in the management of patients experiencing irAEs secondary to ICI’s.